XOMA (NASDAQ:XOMA) Receives Buy Rating from HC Wainwright

XOMA (NASDAQ:XOMA - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $123.00 price objective on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 353.04% from the company's current price.

XOMA Price Performance

Shares of XOMA traded down $0.88 during trading hours on Friday, hitting $27.15. 24,615 shares of the company were exchanged, compared to its average volume of 31,583. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a market capitalization of $319.83 million, a PE ratio of -7.80 and a beta of 0.88. The firm has a fifty day simple moving average of $30.05 and a 200-day simple moving average of $27.69. XOMA has a one year low of $15.56 and a one year high of $35.00.

Insider Buying and Selling

In related news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.20% of the stock is currently owned by company insiders.

Institutional Trading of XOMA

A number of hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA during the first quarter worth $212,000. Bank of New York Mellon Corp raised its stake in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock valued at $230,000 after buying an additional 1,334 shares during the last quarter. Ellsworth Advisors LLC bought a new stake in shares of XOMA in the 3rd quarter valued at approximately $516,000. Finally, BNP Paribas Financial Markets grew its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after buying an additional 795 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.